Home › Funds › Bracebridge Capital, LLC › RNA
Bracebridge Capital, LLC position in RNA
ATRIUM THERAPEUTICS INC · Health Care
Bracebridge Capital, LLC reported holding 139,239 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.9M, representing 0.47% of its reported portfolio and ranking #16 among its reported holdings. Bracebridge Capital, LLC has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bracebridge Capital, LLC's RNA position evolved
Bracebridge Capital, LLC first disclosed a stake in RNA in Q1 2026 at 139,239 shares (US$1.9M). The position peaked in Q2 2026 at 139,239 shares, worth US$1.9M. Across 2 filings, Bracebridge Capital, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 139,239 shares valued at US$1.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 139.24K | $1.86M | New |
| Q2 2026 | 139.24K | $1.87M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 116 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), CRCM LP (US$8.6M), TIG Advisors, LLC (US$7.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $20.18M · Q2 2026
- CRCM LP 641.54K sh · $8.63M · Q2 2026
- TIG Advisors, LLC 561.53K sh · $7.55M · Q2 2026
- Arbiter Partners Capital Management LLC 261.29K sh · $3.51M · Q2 2026
- Slotnik Capital, LLC 237.64K sh · $3.20M · Q2 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 150.03K sh · $2.02M · Q2 2026
- Yakira Capital Management, Inc. 133.05K sh · $1.79M · Q2 2026
- Creek Drive Management Group LLC 127.60K sh · $1.72M · Q2 2026
- Athos Capital Ltd 107.97K sh · $1.45M · Q2 2026
- Marble Bar Asset Management LLP 103.85K sh · $1.40M · Q2 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 43.76K sh · $588.54K · Q2 2026
- Trium Capital LLP 58.38K sh · $483.40K · Q3 2026
More on Bracebridge Capital, LLC
FAQ
How long has Bracebridge Capital, LLC held RNA?
Bracebridge Capital, LLC has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Bracebridge Capital, LLC's current position in RNA?
As of Q2 2026, Bracebridge Capital, LLC holds 139.24K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $1.87M, representing 0.47% of its reported portfolio and ranking #16.
Has Bracebridge Capital, LLC been buying or selling RNA?
In the latest 13F filing (Q2 2026), Bracebridge Capital, LLC held unchanged its position in RNA. The position peaked in Q2 2026 at 139.24K shares.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., CRCM LP, TIG Advisors, LLC, among 116 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.